Showing 1 to 12 of 44 results
DIPG Tumor Research: Insights from Lucía's Legacy
The donated tumor samples of 8-year-old Lucía García, who died of DIPG, a rare and aggressive brain cancer, have enabled breakthroughs in understanding its evasion of the immune system and potential therapeutic targets.
DIPG Tumor Research: Insights from Lucía's Legacy
The donated tumor samples of 8-year-old Lucía García, who died of DIPG, a rare and aggressive brain cancer, have enabled breakthroughs in understanding its evasion of the immune system and potential therapeutic targets.
Progress
12% Bias Score
Trump Administration's Funding Cuts Halt Five Canadian Childhood Cancer Trials
The Trump administration's cuts to scientific funding and restrictions on grants shared with foreign researchers have forced the closure of at least five cutting-edge clinical trials for childhood cancer in Canada, impacting patients' access to potentially life-saving treatments.
Trump Administration's Funding Cuts Halt Five Canadian Childhood Cancer Trials
The Trump administration's cuts to scientific funding and restrictions on grants shared with foreign researchers have forced the closure of at least five cutting-edge clinical trials for childhood cancer in Canada, impacting patients' access to potentially life-saving treatments.
Progress
16% Bias Score
Spanish Scientists Develop BO-112: A Breakthrough in Melanoma Treatment
Juana Santiago's metastatic melanoma, resistant to standard immunotherapy, went into remission after treatment with BO-112, a new drug developed by Spanish researchers at the CNIO, highlighting a breakthrough in melanoma treatment and the importance of clinical trials.
Spanish Scientists Develop BO-112: A Breakthrough in Melanoma Treatment
Juana Santiago's metastatic melanoma, resistant to standard immunotherapy, went into remission after treatment with BO-112, a new drug developed by Spanish researchers at the CNIO, highlighting a breakthrough in melanoma treatment and the importance of clinical trials.
Progress
44% Bias Score
EMA Conditionally Approves Alzheimer's Drug Donanemab Under Strict Monitoring
The European Medicines Agency conditionally approved Eli Lilly's Donanemab for early-stage Alzheimer's patients with one or zero copies of a specific gene, reversing its initial rejection due to the risk of fatal brain swelling and bleeding, mirroring a similar approval process for Lecanemab.
EMA Conditionally Approves Alzheimer's Drug Donanemab Under Strict Monitoring
The European Medicines Agency conditionally approved Eli Lilly's Donanemab for early-stage Alzheimer's patients with one or zero copies of a specific gene, reversing its initial rejection due to the risk of fatal brain swelling and bleeding, mirroring a similar approval process for Lecanemab.
Progress
40% Bias Score
FDA Rejects Promising Drug for Rare Mitochondrial Diseases
The FDA rejected elamipretide, a drug showing promise for treating rare mitochondrial diseases like MLS syndrome, despite positive patient testimonials and an advisory committee's narrow recommendation, raising concerns about the future of drug development for ultra-rare conditions.
FDA Rejects Promising Drug for Rare Mitochondrial Diseases
The FDA rejected elamipretide, a drug showing promise for treating rare mitochondrial diseases like MLS syndrome, despite positive patient testimonials and an advisory committee's narrow recommendation, raising concerns about the future of drug development for ultra-rare conditions.
Progress
48% Bias Score
ICH E21 Guideline Seeks to Include Pregnant and Breastfeeding Women in Drug Trials
A new guideline, ICH E21, aims to address the underrepresentation of pregnant and breastfeeding women in drug trials, which currently leads to these women being denied access to newer, more effective medications due to a lack of safety and efficacy data; this is especially relevant for conditions li...
ICH E21 Guideline Seeks to Include Pregnant and Breastfeeding Women in Drug Trials
A new guideline, ICH E21, aims to address the underrepresentation of pregnant and breastfeeding women in drug trials, which currently leads to these women being denied access to newer, more effective medications due to a lack of safety and efficacy data; this is especially relevant for conditions li...
Progress
20% Bias Score
Wearable Tech Revolutionizes Clinical Trials
Medical-grade wearables are increasingly used in later-stage clinical trials, providing continuous data, improving safety detection, and streamlining trial design, driven by FDA support and patient demand for remote participation.
Wearable Tech Revolutionizes Clinical Trials
Medical-grade wearables are increasingly used in later-stage clinical trials, providing continuous data, improving safety detection, and streamlining trial design, driven by FDA support and patient demand for remote participation.
Progress
48% Bias Score
Stem Cell Therapy: Current Status and Future Prospects
Despite theoretical potential, stem cell applications in tissue repair remain largely in research, with only three treatments—chondrocyte, corneal ligament cells, and engineered skin—currently approved in Spain, highlighting the complexity of regenerating tissues like cardiac muscle.
Stem Cell Therapy: Current Status and Future Prospects
Despite theoretical potential, stem cell applications in tissue repair remain largely in research, with only three treatments—chondrocyte, corneal ligament cells, and engineered skin—currently approved in Spain, highlighting the complexity of regenerating tissues like cardiac muscle.
Progress
16% Bias Score
NeuroScientific Bolsters Leadership Team for StemSmart Commercialization
NeuroScientific Biopharmaceuticals appointed Nathan Smith as CEO and Catherine Cole as chief medical officer, bolstering its team as it prepares for the commercial launch of its StemSmart stem cell technology, acquired through a $4.1 million purchase of Isopgen in June, which treats critically ill p...
NeuroScientific Bolsters Leadership Team for StemSmart Commercialization
NeuroScientific Biopharmaceuticals appointed Nathan Smith as CEO and Catherine Cole as chief medical officer, bolstering its team as it prepares for the commercial launch of its StemSmart stem cell technology, acquired through a $4.1 million purchase of Isopgen in June, which treats critically ill p...
Progress
40% Bias Score
Myasthenia Gravis: Delayed Diagnosis, Economic Burden, and Future Research Needs
Myasthenia gravis (MG), a chronic autoimmune neuromuscular disease affecting approximately 20 per 100,000 people globally, causes muscle weakness and fatigue; delayed diagnosis significantly impacts patients' quality of life and healthcare resource utilization, imposing substantial economic burdens ...
Myasthenia Gravis: Delayed Diagnosis, Economic Burden, and Future Research Needs
Myasthenia gravis (MG), a chronic autoimmune neuromuscular disease affecting approximately 20 per 100,000 people globally, causes muscle weakness and fatigue; delayed diagnosis significantly impacts patients' quality of life and healthcare resource utilization, imposing substantial economic burdens ...
Progress
20% Bias Score
Republican Healthcare Bill to Leave 11.8 Million Uninsured by 2034
The Republican domestic policy bill, if passed, will cause 11.8 million more Americans to be uninsured by 2034 due to over $1 trillion in cuts to Medicaid and other healthcare programs, disproportionately impacting low-income individuals and rural healthcare systems.
Republican Healthcare Bill to Leave 11.8 Million Uninsured by 2034
The Republican domestic policy bill, if passed, will cause 11.8 million more Americans to be uninsured by 2034 due to over $1 trillion in cuts to Medicaid and other healthcare programs, disproportionately impacting low-income individuals and rural healthcare systems.
Progress
48% Bias Score
Trump Administration Explores Psychedelics for PTSD Treatment
The Trump administration is exploring the use of psychedelics, such as MDMA and psilocybin, to treat PTSD and other mental health conditions, based on promising clinical trial results and driven by a need for effective alternative treatments; the Department of Veterans Affairs is currently conductin...
Trump Administration Explores Psychedelics for PTSD Treatment
The Trump administration is exploring the use of psychedelics, such as MDMA and psilocybin, to treat PTSD and other mental health conditions, based on promising clinical trial results and driven by a need for effective alternative treatments; the Department of Veterans Affairs is currently conductin...
Progress
48% Bias Score
Showing 1 to 12 of 44 results